Full Description
Volume 2 of the 5th Edition of the Handbook of Obesity spotlights on clinical applications for evaluation, diagnosis, prevention, and treatment of obesity. It covers on the several major developments occurred between the previous and the new edition, including the effect of SARS-CoV-2 on people with obesity, the concept of "Precision Medicine", and new medications approved by USFDA aiding patients with obesity weight loss of 15 to 20%.
This volume is structured into 5 parts:
Part 1 provides insights from evolution on changes in diet and physical activity, and the implications and results for preventing obesity, health care costs associated with obesity and the cost-effectiveness of obesity prevention and treatment
Part 2 deals with evaluation of overweight patients, approaches for classifying obesity and using this knowledge to evaluate patients, and addressing ethnic and racial considerations in evaluating patients with obesity
Part 3 explains the impact of lifestyle in managing obesity, which include behavioural management, diet, dietary composition, and meal timing, and the effects of physical activity and exercise in weight loss and weight loss maintenance
Part 4 is focused on medications in the management of obesity. This includes drug selection, various classes of drugs, combination of drugs affecting weight loss, effect of herbal agents on weight loss and treatment of obesity in pediatric populations, genetic diseases causing obesity and the role of drugs in treating the dyslipidemias
Part 5 discusses bariatric surgery, its history, procedure and effects in details, and other surgical techniques including electric stimulation of the vagus nerve, gastric balloons, intestinal liners, and liposuction
Contents
Preface. About the Editors. Associate Editors. Contributors. Introduction to Volume 2. PREVENTION AND ECONOMIC OUTCOMES OF OBESITY. Dietary Changes in Human Evolution: Implications for the Prevention of Obesity. Evolutionary Changes in Physical Activity, Diet, and Energy Expenditure: Implications for the Prevention of Obesity. Prevention of Obesity in Adults. The Prevention of Obesity in Children and Adolescents. Re-engineering the Built Environment: Progress in Schools, Worksites, Neighborhoods, and Communities. The Economic Costs of Obesity. Cost-Effectiveness of Obesity Prevention and Treatment. Role of Government and Non-government Organizations in the Obesity Pandemic and Its Prevention. Role of Reimbursement in the Delivery of Treatment for Obesity in Adults and Children. EVALUATION OF THE PATIENTS WITH OVERWEIGHT OR OBESITY. Classification, Evaluation, and Staging of the Patient with Obesity. Indicators of Central Adiposity: A Critical Evaluation of Their Usefulness. Genetic Obesity Syndromes. Ethnic and Racial Considerations in the Evaluation of the Patient with Obesity. LIFESTYLE IN THE MANAGEMENT OF OBESITY: BEHAVIORAL MODIFICATION, DIET, AND EXERCISE. Best Practices: Obesity and the Primary Care Providers. In-Person Behavioral Approaches for Weight Management. Behavioral Interventions Delivered Remotely. Cultural Considerations in Behavioral Therapy for the Management of Obesity. Diet Composition and Weight Loss: Is a Calorie a Calorie? Circadian Rhythms and Weight Loss: Timed Food Intake. Comparison of Modern-Millennial Diets. Dietary Energy Density and Its Contribution to Weight Control. Dietary Patterns as a Basis for Diet Selection. Physical Activity and Weight Loss: Volume, Intensity, and Mode. Modifying Sedentary Behavior for the Prevention and Treatment of Obesity. Preventing Weight Regain after Weight Loss. Personalized and Precision Nutrition in the Management of Obesity: Can We Tailor the Treatment to the Patient? MEDICATIONS IN THE MANAGEMENT OF OBESITY. Drug-Associated Weight Gain and Clinical Alternatives. Mechanisms of Drug Action in Obesity. Metabolic Effects of Progressive Weight Loss. Older Drugs Used to Manage Obesity: Sympathomimetics and Orlistat. Serotonergic Drugs for Treating Obesity. Antidiabetic Drugs That Reduce Weight and Are Cardioprotective. Approved Combination Agents: Phentermine/Topiramate. Approved Combination Agents: Naltrexone-Bupropion. Drugs That Affect Body Weight: The Glucagon-Like Peptide-1. Agonists. Hydrogels in the Treatment of Obesity. Dual and Triple-Action Peptides. Antiobesity Medications on the Horizon. Treatments for Rare Forms of Genetic Obesity. Special Issues in Using Medications in Children and Adolescents. Dietary Supplements and Weight Management. SURGICAL INTERVENTIONS FOR OBESITY. Historical Overview of Metabolic and Bariatric Surgery. Overview: Current Metabolic Operations and Long-Term Outcomes. Effects of Metabolic Surgery on Type 2. Diabetes. Cardiovascular Outcomes in Metabolic Surgery. Effect of Bariatric Surgery on Cancer. Bariatric Surgery in Pediatric Patients. Other Bariatric Procedures: Nerve Stimulation, Gastric Balloons, Intestinal Liners, and Others. Index.
